Antibody Technology Financing and Deal-Making

Venue: Wyndham Emerald Plaza

Location: San Diego, California, United States

Event Date/Time: Apr 08, 2002 End Date/Time: Apr 09, 2002
Report as Spam

Description

FEATURING:

Abgenix
AbTECH S.A.
Affitech A.S.
Altarex Corporation
Amgen
Arius Research
Atopix Pharmaceuticals
Bard Biopharma
Bioscience Ventures, Inc.
Cambridge Antibody Technology
Celltech Group plc
Chiron Corporation
Corixa Corporation
Exelixis Inc.
Forward Ventures
Genentech
Genway Biotech
IDEC Pharmaceuticals
Immunogen Inc.
J.P. Morgan Chase H & Q
Johnson & Johnson
Lexicon Genetics
Medarex
Merck & Company
Protein Design Labs
Raven Biotechnologies
Roth Capital
Wyeth Ayerst


ORGANIZED INTO THREE SECTIONS:

Venture-Backed Antibody & Antibody Mimic Startups

Partnering of Early-Stage Antibody Technologies

Licensing & Deal-Making: The Bigger Picture


KEY INSIGHTS ON:

* Buy-Side & VC Perspective of Antibody Investments
* Bypassing VC's: Obstacles & Opportunities
* Licensing of Early-Stage Antibody Therapeutics
* PDL - Exelixis: Novel Transaction Structure
* The Biotech-Biotech Alliance - Cambridge Antibody Technology
* The Lexicon - Abgenix Collaboration
* Mab Partnering - Corixa
* Creative Deal Structuring - Celltech Group plc
* Maximum Adaptability Partnering Strategy: Medarex - KIRIN

KEYNOTE PRESENTATION:

Wall Street's View on Antibody Financing

Fariba F. Ghosian, Ph.D.
Managing Director, Healthcare Research
Financial Analyst
ROTH CAPITAL PARTNERS

Tom Redington
REDINGTON INC.

Venue

Types